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ABSTRACT
Macrolide resistance among Streptococcus pyogenes (group A streptococci) in Portugal was stable during
1998–2003, but a rapid inversion in the dominant phenotypes was noted in the same period, with a sharp
decrease in the proportion of isolates presenting the MLSB phenotype and a concomitant increase in
isolates presenting the M phenotype. The characterization of group A streptococci recovered during
2004–2006, which is reported here, revealed that resistance was not stable during this period and that the
decline in erythromycin resistance observed during 2004–2006 was due to a decrease in the prevalence
of isolates presenting the M phenotype, while the proportion of isolates expressing the MLSB phenotype
remained stable. Characterization by emm typing, T serotyping, pulsed-ﬁeld gel electrophoresis (PFGE)
proﬁling and multilocus sequence typing revealed a very diverse population. Several of the major PFGE
clusters identiﬁed had already been found in the 1998–2003 study period, but others were found for the
ﬁrst time, e.g. T11 ⁄ emm11 ⁄ ST403, carrying the erm(B) gene, and T3 ⁄ 13 ⁄ emm3 ⁄ ST315, carrying the mef(A)
gene. The clone deﬁned as T12 ⁄ emm12 ⁄ ST36, previously found to be associated with mef(A), was now
found to be predominantly associated with erm(B). The clonal dynamics of macrolide-resistant group A
streptococci emphasizes the importance of considering factors other than antibiotic consumption in
explaining the prevalence of resistant isolates.
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INTRODUCTION
Streptococcus pyogenes, Lanceﬁeld group A strep-
tococci (GAS), is an important human pathogen
causing a wide variety of infections, from severe
life-threatening diseases to pharyngitis, an infec-
tion for which it is the most common bacterial
aetiological agent. b-Lactams remain the antibiot-
ics of choice in the treatment of GAS pharyngitis,
and macrolides and lincosamides are the ﬁrst-
line alternatives. Although macrolide resistance
in GAS remained at low levels for a long time,
a number of recent studies have reported an
increase in resistance. Two different mechanisms
have been recognized in macrolide-resistant
S. pyogenes: target site modiﬁcation and active
efﬂux. Target site modiﬁcation occurs in the
ribosome via an erythromycin resistance methyl-
ase (Erm) protein, blocking the binding of
macrolides, lincosamides and streptogramin B
(generating the MLSB phenotype) [1]. In GAS, the
MLSB phenotype can be mediated by two classes
of methylase genes, the erm(B) determinant and
the erm(TR) determinant (belonging to the erm(A)
class) [2]. The expression of the erm genes can be
either constitutive or inducible, generating the
cMLSB phenotype or the iMLSB phenotype,
respectively, the latter frequently being associated
with the erm(A) class. Both classes of erm genes
were found to be associated with transposons that
were shown to have the capacity to transfer the
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resistance traits to susceptible isolates by conju-
gation [3]. The second mechanism conferring
macrolide resistance in GAS is mediated by a
membrane-associated pump encoded by the mef
genes, leading to resistance to 14- and 15-mem-
bered ring macrolides (generating the M pheno-
type) [4]. The mef(A) and mef(E) variants are
widely distributed in streptococci [5], although
the mef(A) variant associated with a phage-like
element was found in the majority of GAS with
the M phenotype [6]. Other mechanisms of
resistance resulting from mutations, such as
alterations of the ribosomal proteins, are infre-
quently observed in isolates responsible for infec-
tions, and currently have little clinical impact [7].
The factor most frequently associated with
increases in antimicrobial resistance is antimicro-
bial consumption [8,9]. An association between
macrolide consumption and resistance in GAS
was shown in ecological studies [9,10], with
intermediate-acting (e.g. clarithromycin) and, par-
ticularly, long-acting (e.g. azithromycin) macro-
lides being implicated in enhanced resistance
selection [11]. Further supporting this association,
it was noted that a sharp decrease in macrolide
prescribing was accompanied by a decline in
macrolide-resistant GAS [12]. More recently, stud-
ies at the individual level conﬁrmed and extended
these ﬁndings by showing a causal relationship
between both clarithromycin and azithromycin
treatment and selection for macrolide-resistant
streptococci [13]. Furthermore, the latter study
implicated clarithromycin, but not azithromycin,
in the selection for the erm(B) gene. In spite of the
recognized importance of antibiotic consumption
in the selection of resistant strains, the largely
clonal structure of most bacterial populations [14],
including GAS [15,16], suggests that the circulat-
ing clonesmay also contribute signiﬁcantly to both
the prevalence of resistance phenotypes and the
overall level of resistance. The transmissibility of
the genetic elements carrying the resistance deter-
minants may also inﬂuence their prevalence in the
population, with the more easily disseminated
elements having an advantage over less mobile
genetic determinants [17].
We have previously shown that, although
erythromycin resistance in GAS remained above
20% in Portugal from 1998 to 2003, this was not
associated with a stable population of macrolide-
resistant S. pyogenes [18]. Indeed, the predomi-
nance of the MLSB phenotype, which accounted
for c. 80% of isolates in 1998, was completely
reversed in 2003, when almost 77% of the isolates
expressed the M phenotype [18]. We have also
found these changes to be associated with the
decline of a particular clone expressing the MLSB
phenotype and the emergence of several clones
expressing the M phenotype [16]. Here we report
the continuing ﬂuctuations in macrolide resis-
tance phenotypes and a decline in overall eryth-
romycin resistance.
MATERIALS AND METHODS
Bacterial isolates and identiﬁcation
In total, 1184 S. pyogenes isolates recovered from throat swabs
and associated with a diagnosis of tonsillopharyngitis were
collected from 31 microbiology laboratories located through-
out Portugal from January 2004 to December 2006. The
laboratories were asked to submit all non-duplicate S. pyogenes
isolates from outpatients during the study period. The isolates
were collected in the study period as follows: 284 in 2004, 392
in 2005, and 508 in 2006; only a little over 5% of the isolates
were recovered from adults (‡18 years). The proportion of
isolates submitted by laboratories from each of the major
regions of Portugal was constant relative to the previous study
period [18]. Isolates were identiﬁed to the species level by
colony morphology, b-haemolysis on horse blood agar, and a
commercial latex agglutination technique (Slidex Strepto A;
BioMe´rieux, Marcy l’Etoile, France). In this collection, 156
isolates (13.2%) were erythromycin-resistant, and only these
isolates were characterized further.
Antimicrobial susceptibility testing and macrolide resistance
phenotype
Susceptibility to erythromycin, clindamycin and tetracycline
(Oxoid, Basingstoke, UK) was tested using disk diffusion
according to CLSI recommendations [19]. The macrolide
resistance phenotype was determined according to a double-
disk test previously described [20].
Bacitracin susceptibility was determined for all isolates by
disk diffusion using disks containing 0.05 U of bacitracin
(Oxoid, Basingstoke, UK) as previously described [16]. The
absence of an inhibition zone around the disk was interpreted
as resistance.
PCR determination of the macrolide and tetracycline
resistance genotype
Total bacterial DNA was isolated according to the methodol-
ogy described by the CDC (http://www.cdc.gov/ncidod/
biotech/strep/protocols.htm). PCR reactions to determine
which of the macrolide resistance determinants (erm(B), erm(A)
or mef) was present were performed as described previously
[21]. To discriminate between mef(A) and mef(E), mef
was ampliﬁed by PCR using primers MEFR (5¢-CCAATGA
TTTACACCGATT-3¢), MEF1 (5¢-AATACAACAATTGGAA
ACTT-3¢) and MEF2 (5¢-AAGGAGTTGTGGTTCTGA-3¢), as
previously described (Go´mez E, de la Pedrosa G, van der
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Linden M et al. Presented at the 47th Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC),
Chicago, 17–20 September 2007).
PCR reactions for the detection of the tetracycline resistance
determinants tet(K), tet(L), tet(M) and tet(O) were performed
for all isolates included in this study, as previously described
[22]. The Streptococus dysgalactiae subsp. equisimilis strains
SH533, SH523 and 645040, carrying tet(M), tet(O) and tet(L),
respectively, and an Escherichia coli strain carrying the pST181
plasmid with the tet(K) gene were used as positive controls.
T and emm typing
T typing was done by slide agglutination using sera for
types 1, 2, 3, 4, 6, 8, 9, 11, 12, 13, 18, 22, 23, 25, 28, 5 ⁄ 27 ⁄ 44,
14 ⁄ 19, B3264 and Imp. 19 (Hemolytic streptococcus Typing
Antisera for Group A (T-typing), Seiken, Denka Seiken, Tokyo,
Japan), according to the manufacturer’s instructions. emm
typing was performed as described by the CDC (http://
www.cdc.gov/ncidod/biotech/strep/protocols.htm). Ampli-
ﬁcation products were puriﬁed using the High Pure PCR
Product Puriﬁcation Kit (Roche, Mannheim, Germany), accord-
ing to the manufacturer’s instructions, and sequenced using
primer emmseq2 [23], and the DNA sequences were searched
against the emm sequences deposited in the CDC database
(http://www.cdc.gov/ncidod/biotech/strep/strepindex.htm).
An isolate was considered to be of a given emm type if it had
>95% identity over the 160 bases considered [23].
Pulsed-ﬁeld gel electrophoresis (PFGE) and multilocus
sequence typing (MLST)
PFGE was performed as previously described [24]. All isolates
were digested with SmaI, and the isoschizomer Cfr9I was used
only for the isolates with the M phenotype, which were not
digested by SmaI, due to the presence of a methyltransferase
encoded in the same genetic element that carries the mef(A)
gene [6,16]. Bionumerics software (Applied-Maths, Sint-Mar-
tens-Latem, Belgium) was used to create UPGMA (unweighted
pair-group method with arithmetic mean) of the SmaI- or
Cfr9I-generated fragment patterns. The Dice similarity coefﬁ-
cient was used, with optimization and position tolerance
settings of 1.0 and 1.5, respectively. PFGE clusters were
deﬁned as isolates with ‡80% similarity [24]. A PFGE-based
cluster was considered to be a major lineage if it included more
than ﬁve isolates. MLST analysis was performed in represen-
tatives of each major lineage, as previously described [25], and
allele and sequence type (ST) were attributed using the
S. pyogenes MLST database (spyogenes.mlst.net).
Statistical analysis
Wallace coefﬁcients (W) were used to compare partitions. This
coefﬁcient indicates the probability that two isolates sharing
the same characteristic, as established using a given typing
method, will also be grouped together when a different typing
method is used [24]. Simpson’s index of diversity (SID) and
corresponding 95% CIs were used to evaluate the clonal
diversity of the isolates presenting the M and the MLSB
phenotypes [24].
Statistically signiﬁcant differences in proportions of resis-
tant isolates were detected using the two-tailed Fisher exact
test, trends in macrolide resistance were evaluated using the
Cochran–Armitage test for trend [26], and 95% CIs were
calculated using the Wilson method [27].
RESULTS
Antimicrobial susceptibility
During the 3 years of the study, the overall rate of
erythromycin resistance was 13.2%, lower than
that documented previously (26.6%, Fisher’s
exact test, p <10)6) [18]. In 2004, 50 isolates were
erythromycin-resistant (17.6%), the highest resis-
tance rate, followed by 11% (n = 43) in 2005 and
12.4% (n = 63) in 2006, with a signiﬁcant decreas-
ing trend (Cochran–Armitage test for trend,
p <10)4). Inspection of Fig. 1 shows that the
decline in resistance in the 2004–2006 period
was due to a decline in isolates of the M
phenotype, and that this trend of decreasing
erythromycin resistance could have started before
2004. In fact, the Cochran–Armitage test for trend,
which was unable to detect a trend in the period
1999–2003 (p = 0.22), is signiﬁcant if one consid-
ers the entire period 1999–2006 (p <10)4).
The majority of the isolates (n = 80; 51.3%)
presented the cMLSB phenotype, 74 (47.4%)
presented the M phenotype, and only two isolates
(1.3%) presented the iMLSB phenotype; however,
the prevalence of the macrolide-resistance pheno-
types was not constant during the study period
(Fig. 1). Resistance to tetracycline was found in
19.9% (n = 31) of the macrolide-resistant isolates,
all expressing the MLSB phenotype; in fact, the











Fig. 1. Erythromycin resistance and prevalence of macro-
lide resistance phenotypes in Portugal during the period
1998–2006. Open circles and solid lines represent the
proportion of erythromycin-resistant group A streptococci
among those causing pharyngitis and corresponding
95% CIs. Broken lines represent the proportion of each
phenotype in the population. Solid triangles represent the
proportion of isolates of the M phenotype. Open triangles
represent the proportion of isolates of the MLSB phenotype.
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predictor of tetracycline resistance (W = 0.739).
The distribution of tetracycline-resistant isolates
during the study years was as follows: 20.0%
(n = 10) of the isolates recovered in 2004, 11.6%
(n = 5) in 2005, and 25.4% (n = 16) in 2006.
Resistance to bacitracin was found in 43 isolates,
all presenting the cMLSB phenotype.
Genotypic characterization
Erythromycin resistance determinants were de-
tected in all isolates using multiplex PCR. With
the exception of seven isolates, all carried a single
macrolide resistance determinant (Table 1). All
isolates of the M phenotype carried mef(A) and
none the mef(E) variant, including two that carried
both mef(A) and erm(B) and an isolate that carried
mef(A) and erm(A). Four of the isolates presenting
the cMLSB phenotype (4.9%) carried both erm(B)
and mef(A), whereas all other isolates presenting
this phenotype yielded a single PCR product
consistent with the presence of erm(B). One of the
two isolates presenting the iMLSB phenotype
carried erm(A) and the other erm(B).
The tet(M) gene was found among all tetracy-
cline-resistant isolates. None of the other
tet determinants was found among the studied
isolates, including all phenotypically tetracycline-
susceptible isolates.
Clonal characterization
The emm types most frequently found in this
study were emm28 (28%), emm4 (25%) and emm11
(11%). Other emm types accounted for 37% of the
isolates, but each for less than 10% (emm1, emm2,
emm3, emm4, emm6, emm12, emm22, emm44–61 and
emm75). The most prevalent T types were T28
(25%), T4 (21%), T12 (17%) and T3 ⁄ 13 (12%), and
the remaining 24% of the isolates were T1, T6,
T11, T25 or were non-typeable.
All 156 isolates were typeable by PFGE using
either SmaI or Cfr9I, and 25 (16%) of the isolates
were analysed using MLST. Eight major lineages
were identiﬁed, containing 139 isolates (89%),
and the remaining isolates (n = 17) were included
in minor PFGE clusters (containing four or fewer
isolates) or had unique PFGE patterns. The PFGE
patterns of representative isolates from each
major clone are shown in Fig. 2 and the charac-
teristics of the eight major lineages found in this
Table 1. Properties of macrolide-resistant Streptococcus
pyogenes responsible for pharyngitis isolated in Portugal




isolates (%) T ⁄ emm Phenotype Genotype ST
Year
2004 2005 2006
A 42 (26.9) 28 ⁄ 28a cMLSB erm(B)b 52 10 17 15
B 39 (25) 4 ⁄ 4c M mef(A)d 39 18 14 7
C 16 (10.3) 11 ⁄ 11e cMLSB erm(B) 403 4 3 9
D 11 (7.1) 12 ⁄ 22 cMLSB erm(B)f 46 5 1 5
E 10 (6.4) 3 ⁄ 13 ⁄ 3 M mef(A) 315 0 0 10
F 8 (5.1) 25 ⁄ 75 M mef(A) 150 3 1 4
G 7 (4.5) 12 ⁄ 12 cMLSBg erm(B)g 36 1 2 4
H 6 (3.8) 1 ⁄ 1 M mef(A)h 28 3 3 0
Otheri 17 (10.9) 6 2 9
PFGE, pulsed-ﬁeld gel electrophoresis; ST, sequence type.
aNT ⁄ 28 (n = 2); 12 ⁄ 28 (n = 2).
bTwo isolates carried both erm(B) and mef(A).
c3 ⁄ 13 ⁄ 4 (n = 5); 3 ⁄ 13 ⁄ 2 (n = 1); 3 ⁄ 13 ⁄ 3 (n = 1).
dOne isolate carried both erm(B) and mef(A) and one isolate carried both mef(A) and
erm(A).
e12 ⁄ 11 (n = 3).
fTwo isolates carried both erm(B) and mef(A).
gOne isolate had the iMLSB phenotype and carried erm(A).
hOne isolate carried both mef(A) and erm(A).
iTwelve T ⁄ emm type combinations were distributed among ten PFGE clusters. All
three macrolide resistance phenotypes were found among these isolates: M
phenotype (n = 10), all carrying the mef (A) gene; cMLSB phenotype (n = 6), all











Fig. 2. Pulsed-ﬁeld gel electrophoresis (PFGE) analysis of
macrolide-resistant Streptococcus pyogenes isolates from
Portugal. (a) Dendrogram showing cluster analysis of the
PFGE proﬁles of the 156 macrolide-resistant isolates by the
unweighted pair-group with arithmetic mean (UPGMA)
method. Dice coefﬁcients (percentages) are indicated in the
scale above the dendrogram. For each of the major clones,
a triangle proportional to the number of isolates is shown
in the dendrogram, followed by the capital letter desig-
nating the PFGE cluster. (b) PFGE proﬁles generated
following SmaI (MLSB isolates) or Cfr9I (M isolates)
digestion of DNA isolated from representatives of each
major clone. Capital letters identifying each lane corre-
spond to the clone designations. m, lambda ladder PFGE
marker (New England Biolabs, Beverly, MA, USA).
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study, as well as their distribution during the
study period, are summarized in Table 1. The
PFGE cluster classiﬁcation was an excellent
predictor of both the macrolide resistance pheno-
type and the emm type (W = 0.995 and W = 0.958,
respectively).
PFGE cluster A accounted for 27% (n = 42) of
the isolates and included exclusively the cMLSB
phenotype. All isolates in this cluster carried the
emm28 allele and the erm(B) gene, including two
isolates that additionally carried mef(A), and all
were susceptible to tetracycline and, unusually,
resistant to bacitracin. Most isolates in this cluster
were T28, with the exception of two isolates that
were non-typeable and two isolates that were T12.
All the isolates characterized by MLST (n = 4),
including one with the T12 serotype, belonged to
ST52. A single bacitracin-resistant isolate was not
grouped into any of the major PFGE clusters but
had the same characteristics as these isolates
(T28 ⁄ emm28 ⁄ ST52).
Cluster B included only isolates of the M
phenotype and they were susceptible to tetra-
cycline, and accounted for 25% (n = 39) of the
isolates. All the isolates carried mef(A), including
two isolates that, in addition, also carried either
erm(B) or erm(A). Although almost all the isolates
were T4, a signiﬁcant proportion (n = 7; 17.9%) of
the isolates were T3 ⁄ 13. However, only two of
these seven isolates were of different emm types,
namely emm2 and emm3, whereas all other isolates
of the cluster carried emm4. All isolates analysed
by MLST (n = 6), including the two isolates of
different emm types, were found to belong to ST39.
All the isolates included in cluster C (n = 16,
10.3%) presented the cMLSB phenotype, were
resistant to tetracycline, and carried erm(B). Most
isolates included in this cluster were T11 ⁄ emm11,
with the exception of three isolates, characterized
by the combination T12 ⁄ emm11. All isolates of this
PFGE cluster for which the sequence type was
determined (n = 4), including one T12 ⁄ emm11
isolate, belonged to ST403.
Cluster D comprised 11 cMLSB isolates (7.1%),
which were resistant to tetracycline and had the
same combination of surface antigens, namely
T12 ⁄ emm22. Two isolates carried both erm(B) and
mef(A), and those remaining carried only erm(B).
The three isolates included in this PFGE cluster
analysed by MLST were found to belong to ST46.
All of the isolates grouped in cluster E
(n = 10, 6.4%) presented the M phenotype, were
susceptible to tetracycline, and carried only
mef(A). The T antigen expressed by all of the
isolates was T3 ⁄ 13, and all of them carried the
emm3 allele. MLST was performed for two
isolates, and both belonged to ST315.
Three smaller clusters (F, G and H) comprised
eight, seven and six isolates, respectively. Clus-
ter F included tetracycline-susceptible isolates
displaying the M phenotype and the T25 ⁄ emm75
surface antigens and carrying mef(A). One isolate
was analysed by MLST and belonged to ST150.
Cluster G comprised tetracycline-susceptible
cMLSB isolates, carrying erm(B), with the excep-
tion of one isolate that presented the iMLSB
phenotype and carried erm(A). All seven isolates
were T12 ⁄ emm12, and the two isolates analysed
by MLST were ST36. The smaller cluster, desig-
nated H, included tetracycline-susceptible isolates
presenting the M phenotype, and all except one
carried only mef(A) (the exceptional isolate carried
both mef(A) and erm(A)). All of the isolates were
T1 ⁄ emm1, and the ST found in this cluster was
ST28 (n = 2).
A small proportion (n = 17, 10.9%) of the
isolates was not grouped into any of the clusters
described above. Whereas six had a unique PFGE
pattern, the emm types of another six were found
in major clusters (emm1, emm12 and emm3).
The prevalence of the major clusters was not
stable during the study period (Table 1), and
these ﬂuctuations were reﬂected in the changes
observed in the frequency of the macrolide
resistance phenotypes (Fig. 1). To evaluate
whether the diversity of the clones expressing
each of the main macrolide resistance pheno-
types—MLSB and M—varied during the period
1998–2006, SID and the corresponding 95% CIs
were calculated for each year. The results are
summarized in Fig. 3.
DISCUSSION
The erythromycin resistance rate among GAS
during the period 2004–2006 decreased signiﬁ-
cantly, and included the lowest value foundduring
the last decade in Portugal. Excluding 1998, when
the overwhelming dominance of a single clone
could have inﬂuenced the overall rate of resistance
to erythromycin [16], a re-evaluation of the trend
in the period 1999–2006 revealed a signiﬁcant
decrease in the entire period, contrary to our
previous ﬁndings for the period 1999–2003 [18].
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This steady decrease in resistance, accompanied
by changes in the prevalence of the macrolide
resistance phenotypes, was due to a clonal insta-
bility that continued during the period reported
here. The emergence of clones not detected previ-
ously, such as the PFGE clusters characterized
by T11 ⁄ emm11 ⁄ ST403 and T3 ⁄ 13 ⁄ emm3 ⁄ ST315,
accounting for a large fraction of resistant isolates,
was accompanied by a change in the prevalence of
the clones previously described and even the
disappearance of some clones. Most clusters
retained the same macrolide resistance deter-
minant found in the period 1998–2003, apart
from the unusual PFGE cluster characterized by
T12 ⁄ emm12 ⁄ ST36, which was now exclusively
associated with the MLSB phenotype and the
erm(B) gene, instead of with the M phenotype
detected in the period 1999–2003. With the excep-
tion of a macrolide-resistant clone not previously
described (T3 ⁄ 13 ⁄ emm3 ⁄ ST315), all clones identi-
ﬁed among macrolide-resistant GAS in Portugal
appear to be present in other European countries,
suggesting wide geographical spread of a few
successful clones [1,4,28–31]. However, the diver-
sity of the clones detected in a single geographical
region and the variability of macrolide resistance
determinants carried by otherwise undistinguish-
able isolates strongly suggest that acquisition of
macrolide resistance determinants is also ongoing.
The changes in the clonal composition of the
population could have a profound impact on the
prevalence of the macrolide resistance pheno-
types as well as on overall resistance. To test
whether a reduced diversity of the population
could be implicated in the changes in macrolide
resistance, the SID and 95% CIs for each study
year in the period 1998–2006 were calculated
(Fig. 3). As expected, the initial overwhelming
dominance of the T12 ⁄ emm22 ⁄ ST46 clone [16]
resulted in the lowest SID being determined for
the population expressing the MLSB phenotype;
this then increased steadily until 2000, in parallel
with the decrease in the prevalence of this clone.
The second decline in the prevalence of the MLSB
phenotype, occurring between 2001 and 2003
(Fig. 1), was associated with stable and higher
SIDs, indicating that this decrease could not be
attributed solely to changes in the prevalence of a
single clone, as occurred in 1998, or to a lack of
clonal diversity of the MLSB isolates (Fig. 3). The
SID of the population presenting the M pheno-
type was signiﬁcantly higher than that of the
population presenting the MLSB phenotype up to
2001, during a period of increased prevalence of
the M phenotype, but the two populations
remained undistinguishable for the remainder of
the study period (SIDs with overlapping CIs).
This latter observation does not support a
difference in mobility of the genetic elements
carrying each of the macrolide resistance deter-
minants, which would be expected to result in a
higher diversity of the population associated with
the more mobile genetic elements. It is notewor-
thy that the steady, although not signiﬁcant,
decline in the diversity of the populations dis-
playing both macrolide resistance phenotypes
from 2001 to 2003, occurring in a population
increasingly dominated by a few clones, was
followed by a period of greater variability that
paralleled the changes in the prevalence of each
phenotype. However, large changes in the diver-
sity of the population, apparent in the ﬂuctuations
of SID, continued to occur in the somewhat stable
situation concerning macrolide resistance and
phenotypes reached in the period 2005–2006. This
suggests that, although the clonal composition of
the population and the prevalence of the macro-
lide resistance phenotypes are certainly related,
the overall make-up of the population probably
results from the dynamic interaction between
these two factors, and neither can be assumed to
be the cause of the changes observed in the other.
This study has several limitations that may have
inﬂuenced the results presented. In spite of the
location of the laboratories throughout Portugal,
which covered a large fraction of the population,
only close to 1200 isolates were recovered. Two
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M phenotype
MLSB phenotype
Fig. 3. Simpson’s index of diversity for the population of
macrolide-resistant group A streptococcus (1998–2006).
Simpson’s index of diversity and corresponding 95% CIs
were calculated for the PFGE clusters of macrolide-resistant
Streptococcus pyogenes isolates from each study year.
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number of isolates: (i) the management of pharyn-
gitis relies mainly on rapid antigen tests and
clinical criteria, with culture being infrequently
performed; and (ii) although the laboratories were
asked to submit all GAS associated with the
diagnosis of pharyngitis, an audit to ensure
compliance, which may vary in this type of study,
was not undertaken [32]. The increase in the
number of isolates that was particularly apparent
in the period 2005–2006 was found among all
participating laboratories, and we attribute this
mainly to increased compliancewith our request to
send all GAS isolated in pharyngitis cases. The
alternative explanation would be that there is an
increased incidence of infections caused by mac-
rolide-susceptible GAS which, consequently,
would bias the estimates of macrolide resistance.
However, this seems unlikely, because outbreaks
of macrolide-susceptible GAS would probably be
restricted to a few regions and would not be a
national phenomenon, and no changes were ob-
served in the proportions of isolates from each of
the major regions considered. More importantly,
the proportion of isolates expressing the MLSB
phenotype remained approximately constant in
spite of the increase in the total number of isolates,
whereas only the proportion of isolates expressing
theMphenotype decreased in recent years (Fig. 1).
This study showed a decline in macrolide
resistance among GAS causing pharyngitis in
Portugal. These changes were accompanied by
clonal variations, but the great diversity of the
populations displaying each of the macrolide
resistance phenotypes precludes the simple expla-
nation that these could be solely attributed to
strong ﬂuctuations in a few resistant clones. The
results underscore the importance of considering
both the clonal structure of the bacterial popula-
tion and antibiotic consumption when attempting
to explain the prevalence of resistant isolates.
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